← All trials
NCT00161824
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2001
- Primary completion
- —
- Completion date
- Jan 1, 2002
- First posted
- —
- Last posted
- —
- Enrollment
- 3800
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- PfizerLead sponsor
- Zespol Opieki Zdrowotnej w DebicyOverall official - principal investigator
- Przedsiebiorstwo Uslug Medycznych Centrum Medyczne Nowa HutaOverall official - principal investigator
- Atopia Diagnostyka i Leczenie Chorob Alergicznych i Ukladu OddechowegoOverall official - principal investigator
- Szpital Jana Pawla II Oddzial NeuoinfekcjiOverall official - principal investigator
- Wojewodzki SzpitalOverall official - principal investigator
- Pantamed sp. z o o.Overall official - principal investigator
- Samodzielny Publiczny SzpitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.